Gts Securities LLC Bluebird Bio, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$0.47 - $1.35 $9,024 - $25,920	-19,200 Reduced 41.56%	27,000 $14,000
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $14,025 - $20,790	-16,500 Reduced 26.32%	46,200 $45,000
Q1 2024 May 15, 2024	SELL	$0.91 - $1.75 $160,160 - $308,000	-176,000 Reduced 73.73%	62,700 $80,000
Q4 2023 Feb 14, 2024	BUY	$1.32 - $4.83 $167,244 - $611,961	126,700 Added 113.13%	238,700 $329,000
Q3 2023 Nov 15, 2023	BUY	$3.02 - $4.05 $338,240 - $453,600	112,000 New	112,000 $340,000

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $677M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.